Literature DB >> 15621800

Expression of CCR4 in adult T-cell leukemia.

Osamu Yoshie1.   

Abstract

Adult T-cell leukemia (ATL) is a malignancy of mature T cells that is etiologically associated with human T-cell leukemia virus type 1 (HTLV-1). The frequent manifestation of ATL is infiltration of leukemic cells into various organs. Besides certain cell adhesion molecules and matrix metalloproteineses, chemokine receptors may play important roles in tissue infiltration of ATL. Identification of a unique set of chemokine receptors expressed by ATL would thus provide valuable information about the molecular mechanism of tissue infiltration of ATL. This may also reveal that ATL frequently develops from a certain subset of T cells that express a particular set of chemokine receptors. Since HTLV-1 encodes a potent viral transcriptional activator Tax, which is known to induce various cellular genes, expression of some chemokine receptors may be affected by Tax. This, however, may relate more to HTLV-1-infected T cells, since ATL cells usually do not express Tax. Finally, identification of a unique set of chemokine receptors expressed by ATL may also provide a new therapeutic target. These considerations prompted us to examine the chemokine receptor expression in ATL. We found that in the majority of ATL cases, leukemic cells consistently express CCR4. Since CCR4 is known to be involved in T cell migration into skin, this may in part explain the frequent skin infiltration in ATL. Furthermore, CCR4 is known to be selectively expressed by Th2 and regulatory T cells. Thus, the majority of ATL may predominantly originate from either Th2 or regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15621800     DOI: 10.1080/10428190400007607

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

Review 1.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

2.  CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells.

Authors:  Mari Masuda; Tomoko Maruyama; Tsutomu Ohta; Akihiko Ito; Tomayoshi Hayashi; Kunihiko Tsukasaki; Shimeru Kamihira; Shoji Yamaoka; Hiroo Hoshino; Teruhiko Yoshida; Toshiki Watanabe; Eric J Stanbridge; Yoshinori Murakami
Journal:  J Biol Chem       Date:  2010-03-09       Impact factor: 5.157

3.  Human T-cell leukemia virus type-1 Tax oncoprotein regulates G-protein signaling.

Authors:  Jean-Claude Twizere; Jean-Yves Springael; Mathieu Boxus; Arsène Burny; Franck Dequiedt; Jean-François Dewulf; Julie Duchateau; Daniel Portetelle; Patrice Urbain; Carine Van Lint; Patrick L Green; Renaud Mahieux; Marc Parmentier; Luc Willems; Richard Kettmann
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

4.  The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab.

Authors:  Lan Wang; Miriam Bargout; Jane Date Hon; Bassam Yaghmour; Ann Mohrbacher; George Yaghmour
Journal:  World J Oncol       Date:  2020-02-02

Review 5.  Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease.

Authors:  Natsumi Araya; Tomoo Sato; Naoko Yagishita; Hitoshi Ando; Atae Utsunomiya; Steven Jacobson; Yoshihisa Yamano
Journal:  Viruses       Date:  2011-08-25       Impact factor: 5.048

6.  The Impact of Immune Response on HTLV-I in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

Authors:  Houshang Rafatpanah; Reza Farid Hosseini; Seyed Hassan Pourseyed
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

7.  Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.

Authors:  Masao Nakagawa; Roland Schmitz; Wenming Xiao; Carolyn K Goldman; Weihong Xu; Yandan Yang; Xin Yu; Thomas A Waldmann; Louis M Staudt
Journal:  J Exp Med       Date:  2014-12-08       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.